Seeking Private Sector Input into the Global Fund’s Future Strategy: Upcoming Consultations for Business

Nisa PatelArticle

The PSD is seeking input from a wide range of Global Fund partners and stakeholders from the business sector into on-going dialogues this year aimed at developing the next Global Fund strategy. The new strategy will cover the five-year period from 2017 to 2021 and will serve as an organizational framework outlining the Fund’s core mission, goals and objectives for … Read More

Nisa PatelSeeking Private Sector Input into the Global Fund’s Future Strategy: Upcoming Consultations for Business

PSD Hosts Event to Highlight Private Sector Role in Strengthening Health Systems

Nisa PatelNews

At a recent convening in Geneva, Global Fund Executive Director Mark Dybul drew attention to opportunities for private sector partners to bring core business expertise to strengthening country health systems. The event, hosted by the PSD on the margins of the 33rd Board meeting in late March, focused on the role that strong health systems play in combatting HIV/AIDS, TB … Read More

Nisa PatelPSD Hosts Event to Highlight Private Sector Role in Strengthening Health Systems

New Board Leadership, Strategy Discussions Take Center Stage at Global Fund 33rd Board Meeting

Nisa PatelArticle

The Global Fund’s Board met in Geneva for its 33rd Meeting from March 30-April 1, where questions of new leadership and future strategic direction took center stage. The PSD held its semi-annual pre-Board meeting on March 29 to review and propose positions on the slate of upcoming Board decisions. Representatives from AbbVie, Accenture Development Partnerships, Anglo American, BD, Eli Lilly, … Read More

Nisa PatelNew Board Leadership, Strategy Discussions Take Center Stage at Global Fund 33rd Board Meeting

PSD Elections for 2015-2017 Board Member and Alternate Board Member: Call for Applications

Nisa PatelNews

The Private Sector Delegation (PSD) to the Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria is now accepting applications for Board Member and Alternate Board Member positions for the upcoming 2015-2017 term. The PSD Board Member and Alternate Board Member will represent the private sector as a voting constituency to the Global Fund’s governance board for a … Read More

Nisa PatelPSD Elections for 2015-2017 Board Member and Alternate Board Member: Call for Applications

32nd Global Fund Board Meeting

Nisa PatelEvent

The Global Fund Board will convene for an in-person meeting on November 19-21st in Montreux, Switzerland. The first day will consist of pre-Board Meeting briefings on key discussion items at the Board Meeting and is open to all Board constituency members.  The Board Meeting will focus on finalizing the Corporate Key Performance Indicators (KPIs) Framework, reviewing the progress on the … Read More

Nisa Patel32nd Global Fund Board Meeting

Global Fund Private Sector Delegation Bi-Annual Pre-Board Meetings

Nisa PatelEvent

The Private Sector Delegation (PSD) will hold its bi-annual meetings ahead of the 32nd Global Fund Board Meeting on November 18-19th in Montreux, Switzerland to develop positions on key decisions facing the Board and to prepare for the Board Meeting deliberations. The PSD will also meet with other constituencies on the Global Fund Board to gather information and perspectives on … Read More

Nisa PatelGlobal Fund Private Sector Delegation Bi-Annual Pre-Board Meetings

Global Fund Private Sector Delegation Retreat

Nisa PatelEvent

The Private Sector Delegation (PSD) will hold its 4th Annual Retreat on October 20-21st in Basel, Switzerland, hosted by PSD Advisory Group member Novartis. The Retreat will focus on setting strategic priorities for next year, discussing PSD positions on key Global Fund issues, and preparing for the upcoming Board Retreat and 32nd Board Meeting in Montreux, Switzerland scheduled for mid-November. The meetings are open … Read More

Nisa PatelGlobal Fund Private Sector Delegation Retreat

Eli Lilly: Searching for New Tuberculosis Drugs

Nisa PatelArticle

Most TB drugs currently approved for treatment are 50+ years old and are required to be taken over a 6-month period to be effective. Compliance with such a long treatment regimen is a challenge, limiting drugs’ effectiveness and contributing to the rise in MDR-TB. As part of its MDR-TB Partnership, Eli Lilly and Company formed innovative partnerships with the Infectious … Read More

Nisa PatelEli Lilly: Searching for New Tuberculosis Drugs

Meet the PSD: Erika Satterwhite & René Cazetien

Nisa PatelArticle

Erika Satterwhite Manager, Global Policy, Mylan René Cazetien Associate Vice President of Operations, Access to Medicines, Sanofi How did Mylan become involved with the Global Fund? Mylan’s decision to join the PSD Advisory Group is rooted in the company’s desire to provide the often-missing generic manufacturer’s perspective in shaping good public policy around the Global Fund’s efforts to combat HIV/AIDS, TB, … Read More

Nisa PatelMeet the PSD: Erika Satterwhite & René Cazetien